Search Results 41-50 of 21972 for Antibody

  1. Prevalence and Predictors of Spike Protein Antibodies in COVID-19 Vaccinated Individuals - Mayo Clinic

    ... antibody development and determine how age and gender may affect the correlation B. Participation eligibility. Participant eligibility includes age, gender ...

  2. Bispecific antibody therapy: T-cell engagement - Mayo Clinic

    Some bispecific antibody therapies link immune T cells directly to cancer cells. One arm of the bispecific attaches to a T cell. The other arm attaches to ...

  3. New antibody test for MS diagnosis - Mayo Clinic

    Mayo Clinic has identified an immunoglobulin kappa value comparable to the detection of oligoclonal bands for the diagnosis of MS. The antibody test is more ...

  4. Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    The purpose of this trial is to identify the RP2D of STI-6129 by assessing the safety, preliminary effectiveness and pharmacokinetics in treating subjects with ...

  5. Doctors & Departments - Mayo Clinic

    This includes combining bispecific antibodies with other powerful therapies and replacing traditional therapies with newer bispecific antibody-based therapies.

  6. Crucial test to identify those who have recovered from COVID-19 and have active immunity

    Antibodies are produced by a person's immune system, and are critical for control and clearance of the virus. Dr. Gregory Poland, a Mayo Clinic COVID-19 and ...

  7. Isotretinoin With or Without Monoclonal Antibody Ch14.18, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma - Mayo Clinic

    Monoclonal antibodies, such as monoclonal antibody Ch14.18, can block tumor growth in different ways. Some block the ability of tumors to grow and spread ...

  8. A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma - Mayo Clinic

    The purpose of this study is to investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple ...

  10. A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in ...